单位：[1]Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China临床科室儿科儿科首都儿科研究所首都医科大学附属北京友谊医院[2]Department of Pediatrics, Chinese PLA General Hospital, Beijing, 100853, China[3]Beijing Hong Jian Medical Device Company, Beijing, 100176, China
Gaucher disease (GD), the most common lysosomal disorders, is a rare autosomal recessive hereditary disease that is caused by deficiency of glucosylceramidase. For now, there are five approved therapies for GD, which are used to treat thousands of patients with GD. Despite success of approved therapies, many unresolved issues attract academic institutions and industry to develop potential therapies to resolve them. This paper updated the latest information about approved therapies and potential curative therapies.
第一作者单位：[1]Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China
通讯作者：
推荐引用方式(GB/T 7714)：
Kong Weijing,Lu Cheng,Ding Yingxue,et al.Update of treatment for Gaucher disease[J].EUROPEAN JOURNAL of PHARMACOLOGY.2022,926:doi:10.1016/j.ejphar.2022.175023.
APA：
Kong Weijing,Lu Cheng,Ding Yingxue&Meng Yan.(2022).Update of treatment for Gaucher disease.EUROPEAN JOURNAL of PHARMACOLOGY,926,
MLA：
Kong Weijing,et al."Update of treatment for Gaucher disease".EUROPEAN JOURNAL of PHARMACOLOGY 926.(2022)
